Abivax SA (ABVX)

9.45
-0.41(-4.16%)
  • Volume:
    25,917
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    9.23 - 10.16
  • Type:Equity
  • Market:France
  • ISIN:FR0012333284

ABVX Overview

Prev. Close
9.86
Day's Range
9.23-10.16
Revenue
-
Open
10.16
52 wk Range
9.23-36.7
EPS
-2.44
Volume
25,917
Market Cap
158.33M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
24,607
P/E Ratio
-
Beta
0.81
1-Year Change
-67.3%
Shares Outstanding
16,754,951
Next Earnings Date
Sep 15, 2022
What is your sentiment on Abivax SA?
or
Market is currently closed. Voting is open during market hours.

Abivax SA News

Abivax SA Company Profile

Abivax SA Company Profile

Employees
29
Market
France

ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell